CR20110078A - Composiciones farmacéuticas de hormonas somatotróficas - Google Patents

Composiciones farmacéuticas de hormonas somatotróficas

Info

Publication number
CR20110078A
CR20110078A CR20110078A CR20110078A CR20110078A CR 20110078 A CR20110078 A CR 20110078A CR 20110078 A CR20110078 A CR 20110078A CR 20110078 A CR20110078 A CR 20110078A CR 20110078 A CR20110078 A CR 20110078A
Authority
CR
Costa Rica
Prior art keywords
pharmaceutical compositions
somatotrophic
hormones
somatotrophic hormones
composition
Prior art date
Application number
CR20110078A
Other languages
English (en)
Inventor
Andrew Naylor
Andrew Lester Lewis
Lisbeth Illum
Original Assignee
Critical Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39722152&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20110078(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Critical Pharmaceuticals Ltd filed Critical Critical Pharmaceuticals Ltd
Publication of CR20110078A publication Critical patent/CR20110078A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a una composición que comprende una hormona somatotrófica; un componente polimérico biodegradable; y un modificador de liberación. Tambien se proporciona un proceso para preparar y usar tal composición.
CR20110078A 2008-07-11 2011-02-11 Composiciones farmacéuticas de hormonas somatotróficas CR20110078A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0812740.9A GB0812740D0 (en) 2008-07-11 2008-07-11 Composition

Publications (1)

Publication Number Publication Date
CR20110078A true CR20110078A (es) 2011-05-03

Family

ID=39722152

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20110078A CR20110078A (es) 2008-07-11 2011-02-11 Composiciones farmacéuticas de hormonas somatotróficas

Country Status (18)

Country Link
US (1) US20110257097A1 (es)
EP (1) EP2317979A2 (es)
JP (1) JP2011527329A (es)
KR (1) KR20110040892A (es)
CN (1) CN102131498A (es)
AU (1) AU2009269818A1 (es)
BR (1) BRPI0915857A2 (es)
CA (1) CA2730325A1 (es)
CL (1) CL2011000063A1 (es)
CO (1) CO6331422A2 (es)
CR (1) CR20110078A (es)
EA (1) EA201170180A1 (es)
GB (2) GB0812740D0 (es)
IL (1) IL210555A0 (es)
MA (1) MA32545B1 (es)
MX (1) MX2011000259A (es)
WO (1) WO2010004299A2 (es)
ZA (1) ZA201101053B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0812742D0 (en) 2008-07-11 2008-08-20 Critical Pharmaceuticals Ltd Process
EP2165919A1 (de) 2008-09-19 2010-03-24 Sika Technology AG Verstärkte Struktur eines Fahrzeugs
CN101972212A (zh) * 2010-10-29 2011-02-16 华侨大学 超临界流体技术制备核壳型复合微球的方法
EP3202824B1 (en) * 2014-09-29 2021-02-17 LG Hausys, Ltd. Polymer powder and method for preparing same

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100210509B1 (ko) * 1996-01-10 1999-07-15 성재갑 지속성 동물 성장 호르몬 제형 및 이의 제조 방법
US6444223B1 (en) * 1999-05-28 2002-09-03 Alkermes Controlled Therapeutics, Inc. Method of producing submicron particles of a labile agent and use thereof
KR20010002589A (ko) * 1999-06-16 2001-01-15 김윤 생리활성물질 함유 생분해성 고분자 마이크로스피어의 제조방법
KR100622996B1 (ko) * 2005-03-03 2006-09-14 한국과학기술원 약물이 봉입된 비다공성 고분자 미립 담체 및 이의 제조방법
SI2079767T1 (sl) * 2006-10-11 2015-01-30 Tolmar Therapeutics, Inc. Priprava biorazgradljivih poliestrov, ki imajo lastnost majhnega izbruha, s superkritično tekočinsko ekstrakcijo

Also Published As

Publication number Publication date
MA32545B1 (fr) 2011-08-01
WO2010004299A3 (en) 2010-11-11
AU2009269818A1 (en) 2010-01-14
ZA201101053B (en) 2012-07-25
KR20110040892A (ko) 2011-04-20
GB0812740D0 (en) 2008-08-20
CA2730325A1 (en) 2010-01-14
MX2011000259A (es) 2011-04-05
IL210555A0 (en) 2011-03-31
WO2010004299A2 (en) 2010-01-14
US20110257097A1 (en) 2011-10-20
CN102131498A (zh) 2011-07-20
CO6331422A2 (es) 2011-10-20
JP2011527329A (ja) 2011-10-27
EA201170180A1 (ru) 2011-08-30
EP2317979A2 (en) 2011-05-11
GB2474001A (en) 2011-03-30
GB201102015D0 (en) 2011-03-23
CL2011000063A1 (es) 2011-09-23
BRPI0915857A2 (pt) 2015-11-03

Similar Documents

Publication Publication Date Title
UY31863A (es) Combinaciones de drogas que comprenden un inhibidor de dgat y un agonista de ppar
EA201001555A1 (ru) Антиоксидативные модуляторы воспаления: производные олеанолевой кислоты с аминовыми и другими модификациями на с-17
JO3172B1 (ar) تركيبة وطريقة وتحضير الصفراء الصناعية
BRPI0717570B8 (pt) composição farmacêutica sólida adequada para administração oral, seu uso e seu processo de produção
CR20120283A (es) Inhibidor de bromodominio de benzodiazepina
ECSP088800A (es) Formulaciones de inhibidores de DPP IV
ES2556585T3 (es) Composiciones que comprenden sulfato de salbutamol
BR112012010650A2 (pt) partícula de liberação
AR060030A1 (es) Diesteres de acidos carboxilicos ramificados
CR20110078A (es) Composiciones farmacéuticas de hormonas somatotróficas
MX2011007267A (es) Composiciones farmaceuticas que comprenden derivados de 2-oxo-1-pirrolidina.
JOP20180077A1 (ar) تركيبات وطرق لحمض صفراوي تخليقي
AR059742A1 (es) Formulaciones farmaceuticas de una forma cristalina anhidra de 2-(3- fluor-4- dihidroxifenil) 7- vinil-1,3- benzoxazol -5-ol
MY155611A (en) Curing agent composition
ECSP12012155A (es) Hidrato del hidrocloruro de agomelatina y
CU20090200A7 (es) Una composición de liberación prolongada que comprende un derivado de somatostatina en micropartículas
EA201101118A1 (ru) Фармацевтические композиции, включающие производные 2-оксо-1-пирролидина
BR112012015194A2 (pt) composições cosméticas de microesferas de pó
BR112012009310B8 (pt) composto derivados de 2-oxo-1-pirrolidinil imidazotiadiazol, uso dos mesmos e composição farmacêutica compreendendo os mesmos
BR112013024982A2 (pt) composições de colagem
BR112013027619A2 (pt) processo d cura para concreto
BRPI1015042A2 (pt) unidades desencadeadoras ácido-lábeis
BR112012025857A2 (pt) método para a redução de pelo menos um componente orgânico volátil em uma composição de polímero
CL2008003711A1 (es) Proceso para preparar una forma de dosificación farmaceutica que comprende florfenicol o un análogo de este; y para recuperar florfenicol o un análogo de una composición farmacéutica.
BR112012010075A2 (pt) composição cosmética compreendendo éster de sapucainha siliconado